Cat. No. | Product name | CAS No. |
DC9512 |
Lazabemide
Featured
Lazabemide(Ro 19-6327/000) is selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and > 100 μM for MAO-B and MAO-A respectively). |
103878-84-8 |
DC11900 |
Lazertinib
Featured
Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations |
1903008-80-9 |
DC7801 |
LB-100
Featured
LB-100 is a small-molecular protein phosphatase 2A(PP2A)inhibitor with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells. |
1632032-53-1 |
DC22765 |
LB-102
Featured
LB-102 (LB-1.2, LB 102) is a a selective dopamine D2/3/5-HT7 inhibitor. |
2227154-23-4 |
DC23329 |
LCH 7749944
Featured
LCH 7749944 (GNF-PF-2356) is a novel and potent PAK4 with IC50 of 14.93 uM, shows weak activity against other PAK family members. |
796888-12-5 |
DC7184 |
Lcl-161
Featured
LCL161 is an oral small molecule antagonist of Apoptosis Proteins (IAPs) that sensitizes a subset of tumors from diverse lineages to treatment with cytotoxic therapies. |
1005342-46-0 |
DC7707 |
LCZ-696
Featured
LCZ696 is a first-in-class dual inhibitor of the angiotensin II receptor(AT II receptor) and neprilysin; a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). |
936623-90-4 |
DC9394 |
LDC000067
Featured
LDC000067(LDC-067) is a highly specific CDK9 inhibitor with IC50 of 32.7 nM for CDK9/cyclin T1; displays 55/125/210/ >227/ >227-fold selectivity for CDK9 versus CDK2/1/4/6/7. |
1073485-20-7 |
DC7999 |
LDC1267
Featured
LDC1267 is a highly selective TAM(Tyro3, Axl and Mer) kinase inhibitor with IC50 of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively. |
1361030-48-9 |
DC10143 |
LDC-4297
Featured
LDC4297 is a novel CDK7 inhibitor. |
1453834-21-3 |
DC8493 |
NVP-LDE225(Erismodegib)
Featured
LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3. |
956697-53-3 |
DC7185 |
LDE225 Diphosphate
Featured
LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3. |
1218778-77-8 |
DC5167 |
Ceritinib(LDK378)
Featured
LDK378 is a highly selective ALK inhibitor with IC50 of 2 nM |
1032900-25-6 |
DC8231 |
LDN-192960 2HCl
Featured
LDN-192960 is a potent and selective inhibitor of haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase). IC50 = 0.010 µm |
184582-62-5 |
DC7451 |
LDN-193189 HCl
Featured
LDN193189 HCl is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively, exhibits 200-fold selectivity for BMP versus TGF-β. |
1435934-00-1 |
DC8034 |
LDN193189 free base
Featured
LDN193189 is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively. |
1062368-24-4 |
DC9432 |
LDN-212320
Featured
LDN-212320(OSU-0212320) is a glutamate transporter EAAT2 activator; enhances EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h. |
894002-50-7 |
DC7586 |
LDN-212854
Featured
LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2, about 2-, 66-, 1641-, and 7135-fold selectivity over ALK1, ALK3, ALK4, and ALK5, respectively. |
1432597-26-6 |
DC7914 |
LDN-214117
Featured
LDN-214117 is a potent and selective ALK2 inhibitor with IC50 of 22 nM; > 100 fold selectivity for ALK5; also inhibits BMP6(IC50=100 nM). |
1627503-67-6 |
DC7610 |
LDN-57444
Featured
LDN-57444 is a reversible, competitive proteasome inhibitor for Uch-L1 with IC50 of 0.88 μM, 28-fold selectivity over isoform Uch-L3. |
668467-91-2 |
DC7947 |
Ledipasvir
Featured
Ledipasvir(GS5885) is an inhibitor of the hepatitis C virus NS5A protein. Ledipasvir is an experimental drug for the treatment of hepatitis C. |
1256388-51-8 |
DC9773 |
LEE011 hydrochloride
Featured
LEE011 Hcl is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
1211443-80-9 |